trial

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

NCTId NCT00086593
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 209 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2005-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
209 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-05
Primary completion
2005-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
lamotrigine

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

39 total
Little Rock, United StatesGarden Grove, United StatesGlendale, United StatesLos Angeles, United StatesPico Rivera, United StatesSan Diego, United StatesSherman Oaks, United StatesCoral Springs, United StatesMaitland, United StatesMiami, United StatesNorth Miami, United StatesWinter Park, United States

Linked catalysts

1
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophren — primary completion2005-07

Facts & assertions

4 sourced
Enrollment
209
Phase
PHASE3
Primary Completion Date
2005-07
Status
COMPLETED
relationships
The graph out of here
drug
lamotrigine
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication